Analysis of nusinersen using a wide-pore reversed-phase YMC Accura Triart Bio C18 column

9 Sept 2026

Therapeutic oligonucleotides present unique analytical challenges, with synthesis and chemical modification often generating closely related impurities that can be difficult to detect and characterize. Achieving reliable separation of these species is essential for ensuring product quality, supporting regulatory requirements, and advancing confidence in oligonucleotide drug development.

In this application note, discover how ion-pair reversed-phase liquid chromatography (IP-RP LC) and liquid chromatography-mass spectrometry (LC-MS) can be used to analyze nusinersen and its associated impurities. Learn how optimized chromatographic conditions improved impurity resolution and enabled confident identification of truncated species. Gain practical insights to strengthen oligonucleotide characterization workflows and support the development of high-quality therapeutics.

Resource details:

Resource type: Application note
Page count: 7
Read time: 11 mins

Links

Tags

OligonucleotidesOligonucleotides are small nucleic acid polymers, usually less than 20 bases in length. Oligonucleotides can be made via enzymatic cleavage or more commonly by chemical synthesis with polymerases. Their use includes FISH, southern blots, microarrays and as primers in PCR. High fidelity synthesis kits and detection systems are available for easy production and detection, respectively.Reversed-Phase ChromatographyOligosBiopharmaceuticalsBiopharmaceuticals are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or for in vivo diagnostics. The most well known example of a biopharmaceutical product, and the first to be approved for therapeutic use, was recombinant human insulin.